Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human B7-2 / CD86 Protein, Fc Tag, Avi Tag (Avitag™), 25µg  

Recombinant Biotinylated Human B7-2 / CD86 Protein, Fc Tag, Avi Tag (Avitag™), 25µg

MABSol® Recombinant Biotinylated Human B7-2 / CD86 Protein, expressed from human 293 cells (HEK293), Fc tag, Avi tag (Avitag™)

Synonym
recombinant, human, biotinylated, protein, CD86,B7-2,B70,CD28LG2

More details

CD6-H82F5-25

Availability: within 7 days

420,00 €

Background
Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

Source
Biotinylated Human B7-2, Fc,Avitag (CD6-H82F5) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Pro 247 (Accession # AAH40261).
Predicted N-terminus: Leu 26

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™).
The protein has a calculated MW of 53.8 kDa. As a result of glycosylation, The protein migrates as 66-100 kDa under reducing (R) condition and 120-140 kDa under non-reducing (NR) condition on SDS-PAGE gel.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
The biotin to protein ratio is 0.5-1 as determined by the HABA assay.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Reconstitute at 200 μg/mL in sterile deionized water.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
No activity loss is observed after storage at:
4-8°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity ( ELISA bioactivity)
Immobilized Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) at 5 μg/mL (100 μL/well) can bind Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) with a linear range of 19-156 ng/mL (QC tested).

References

(1) Chen C, et al., 1994, J. Immunol. 152 (10): 4929–36.
(2) Yadav, D. et al., 2007, J. Immunol. 178: 6236-6241.
(3) Steidl C, et al., 2010, N. Engl. J. Med. 362 (10): 875–85.

Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent.
The purchase of the Acrosbiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.